Overview

Why Invest

Profitable specialty pharmaceutical company with a diversified portfolio

Cipher’s lean operating structure and collaborative approach to commercialization and development enable rapid and efficient scaling while maximizing our profitability.

Solid dermatology platform

Established presence across the Americas

Strong balance sheet

History of positive operating cash flow

Robust pipeline

Proven leadership team

Download Investor Presentation

Latest News

E-mail Alerts

Nov 7, 2024

Cipher Pharmaceuticals Reports Third Quarter 2024 Results

(All figures are presented in U.S. Dollars) Successfully closed the acquisition of the U.S. based Natroba™ business on July 26, 2024 Epuris sales volumes grew 29% compared to Q3 2023, continuing...

Nov 4, 2024

Cipher Pharmaceuticals Schedules Q3 2024 Earnings Release and Conference Call

Cipher Pharmaceuticals Inc. (TSX: CPH) (OTCQX: CPHRF) ("Cipher" or the "Company") today announced that it will release its financial results for the third quarter of 2024 after the market close on...

Oct 8, 2024

Cipher Pharmaceuticals Enhances Leadership Team with Appointment of New Chief Business Officer

Cipher Pharmaceuticals Inc. (TSX: CPH) (OTCQX: CPHRF) ("Cipher" or the "Company") announced today the appointment of Hamed Ghanei as Chief Business Officer ("CBO"). Craig Mull, Interim Chief...

More News >

Ticker

TSXCPH

Q3 2024 Results

Press Release